Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Typical Duster.

<< Previous

Bullboard Posts

Next >>

Comment by TriumphSpitSixon Dec 03, 2020 5:08pm

222 Views

Post# 32033389

RE:RE:RE:RE:RE:Typical Duster.

Selfish I know, but I wouldn't mind a massive dump to $2.40 USD (my current average) or less to load up before the fireworks start.

Also just FYI, Stockhouse is showing the TSX price in CAD ($3.82) not the OTC price in USD ($2.98) even though they're showing ATBPD as the main (bold, larger font) symbol. Wonky.